Bifunctional small molecules targeting PD-L1/CXCL12 as dual immunotherapy for cancer treatment
Binbin Cheng(Wenzhou Medical University), Jianjun Chen(Southern Medical University), Wei Wang(Capital Medical University), Ting Liu(Chinese PLA General Hospital), Wei Pan(South China University of Technology), Yao Xiao(Children's Hospital of Chongqing Medical University), Hao Cao, Shuwen Liu(Zhengzhou University)
Cited by 29
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
|Drug Resistance Updates|2022|257
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway
|Cell Death and Differentiation|2020|212